News

Call for ERC grantees at Science is Wonderful! 2026

Published on | 7 months ago

Programmes
ERC

The ERC is looking for ERC grantees to participate in the 2026 edition of the annual ‘Science is Wonderful!’ science fair. This event is aimed at primary and secondary school students and gives them the opportunity to interact with teams of researchers that showcase their work at booths through live experiments, interactive presentations, floor games, physical challenges and many other creative formats. 

More information on the Science is wonderful! science fair 2026 edition, what is in it for ERC grantees and what is expected from them, the evaluation criteria and the timeline is available in the application form for ERC grantees which is open until 20 October 2025.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1882 articles available search in articles 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.